Biblioteca Virtuale per la Salute – Piemonte – "Le biblioteche non si fanno…crescono" A. Birrell

Sfoglia per AUTORE
LIBERATI AM
Collezione AOU Città della Salute di Torino

Items : 50

Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI). in Cancer / Cancer. 2025 Apr 1;131(7):e35801. doi: 10.1002/cncr.35801.

2025
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Tomassetti S; Lunghi F; Cavazzini F; Pocali B; Binotto G; Tiribelli M; Brociner M; Vallisa D; Falcone AP; Caocci G; De Stefano V; Gardellini A; Elli EM; Bonifacio M; Farina G; Micucci G; Benevolo G; Morsia E; Pastore D; Polizzi V; Tafuri A; Urbano T; Liberati AM; Itri F; Ditonno P; Carli G; Langella M; Ricco A; Impera S; et alii...

IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma. in Blood advances / Blood Adv. 2024 Mar 26;8(6):1541-1549. doi: 10.1182/bloodadvances.2023011251.

2024
AOU Alessandria
AOU Città della Salute di Torino
AOU Novara
ASL Biella

Bonomini L; Vitolo U; Cesaretti M; Esposito F; Pirosa MC; Pinotti G; Dore F; Pisani F; Zanni M; Ghiggi C; Liberati AM; Annibali O; Cabras MG; Celli M; Orsucci L; Tani M; Bruna R; Vanazzi A; Tucci A; Merli F; Balzarotti M; Gaidano G; Sassone M; Zucca E; Botto B; Stathis A; Ferreri AJM; Chiappella A; Conconi A; et alii...

Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study. in Cancers / Cancers (Basel). 2024 Mar 20;16(6):1228. doi: 10.3390/cancers16061228.

2024
AOU Città della Salute di Torino

Mauro FR; Scalzulli PR; Scarfò L; Minoia C; Murru R; Sportoletti P; Frigeri F; Albano F; Di Renzo N; Sanna A; Laurenti L; Massaia M; Cassin R; Coscia M; Patti C; Pennese E; Tafuri A; Chiarenza A; Galieni P; Perbellini O; Selleri C; Califano C; Ferrara F; Cuneo A; Murineddu M; Palumbo G; Scortechini I; Tedeschi A; Trentin L; et alii...

Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells. in Blood cancer journal / Blood Cancer J. 2024 Jun 7;14(1):94. doi: 10.1038/s41408-024-01075-x.

2024
AOU Alessandria
AOU Città della Salute di Torino

Bruno B; Zamagni E; Stefanoni P; Palmieri S; Liberati AM; Monaco F; Annibali O; Galieni P; Garzia M; Olivero M; Rogers J; Ruggeri M; Pescosta N; Pisani F; Tosi P; Pascarella A; Pietrantuono G; Arigoni M; De Sabbata G; Bertamini L; Belotti A; Rota-Scalabrini D; D'Agostino M; Calogero RA; Boccadoro M; Musto P; Gay F;

Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial. in The Lancet. Haematology / Lancet Haematol. 2024 Jul;11(7):e499-e509. doi: 10.1016/S2352-3026(24)00143-1.

2024
AOU Alessandria
AOU Città della Salute di Torino

Della Starza I; Drandi D; Genuardi E; Ciabatti E; Bomben R; De Novi LA; Cavalli M; Guarini A; Grapulin L; Assanto GM; Annechini G; Tani M; Celli M; Mannina D; Mannarella C; Cencini E; Re F; Bigliardi S; Corradini P; Stelitano C; Tucci A; Perrone T; Gaidano G; Musuraca G; Bernuzzi P; Bolis SA; Zilioli VR; Rattotti S; Ferreri AJM; et alii...

IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma. in Haematologica / Haematologica. 2024 Aug 1;109(8):2564-2573. doi: 10.3324/haematol.2023.283918.

2024
AOU Alessandria
AOU Città della Salute di Torino

Bertoni F; Cavalli F; Landi F; Spina M; Re F; Pietrantuono G; Merli M; Houot R; Liberati AM; Haioun C; Devizzi L; Cartron G; Casasnovas RO; Angrilli F; Occhini U; Pulsoni A; Celli M; Califano C; Capochiani E; Cabras MG; Zanni M; Tilly H; Tessoulin B; Conconi A; Palombi F; Cavallo F; Morschhauser F; Gressin R; Marino D; et alii...

Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS). in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2023 Oct 1;41(28):4486-4496. doi: 10.1200/JCO.22.02699. Epub 2023 Jun 9.

2023
AOU Alessandria
AOU Città della Salute di Torino
AOU Novara

Latagliata R; Zini G; D'Errigo MG; Bova I; Delfino IM; Arcadi MT; Cufari P; Rizzo L; Candoni A; Rivellini F; Buccisano F; Stamatoullas-Bastard A; Liberati AM; Impera S; Di Renzo N; Palumbo GA; Fenaux P; Ricco A; Germing U; Molteni A; Bocchia M; Beltrami G; Castelli A; Fattizzo B; Iannì G; Russo E; Guarini A; Tripepi G; Ferrero D; et alii...

High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. in Haematologica / Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116.

2023
AOU Alessandria
AO Cuneo
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara

Foà R; Nanni M; Del Giudice I; Guarini A; Fazi P; Vignetti M; Piciocchi A; Cuneo A; Neri A; De Novi LA; De Propris MS; Pietrasanta D; Mattiello V; Visentin A; Vitale C; Albano F; Molinari MC; Liberati AM; Giordano A; Gottardi D; Galieni P; Patrizi VB; Tani M; Arcari A; Musuraca G; Deodato M; Massaia M; Rigolin GM; Scarfò L; et alii...

Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. in HemaSphere / Hemasphere. 2023 Apr 4;7(4):e837. doi: 10.1097/HS9.0000000000000837. eCollection 2023 Apr.

2023
AOU Città della Salute di Torino
AOU Novara

Ricardi U; Arcaini L; Ferretti VV; Lazic T; Cristinelli C; Dalceggio D; Ferrari S; Pagani C; Pravato S; Visentin A; Alvarez I; Del Giudice I; Annechini G; D'Elia GM; Tartaglia G; Zoboli V; Bonfichi M; Filippi AR; Merli M; Liberati AM; Fabbri A; Ricci F; Nassi L; Puccini B; Gini G; Dogliotti I; Pinto A; Meli E; Botto B; et alii...

Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma. in Blood / Blood. 2022 Sep 22;140(12):1378-1389. doi: 10.1182/blood.2021014270.

2022
AOU Alessandria
AOU Città della Salute di Torino

Hohaus S; Re F; Petrini M; Pavone V; Castellino C; Zanni M; Casaroli I; Benedetti F; Stefani PM; De Luca G; Mantoan B; Evangelista A; Ferrante M; Ghislieri M; Alessandria B; Zaccaria GM; Drandi D; Genuardi E; Grimaldi D; Ferrero S; Musuraca G; Cascavilla N; Ghiggi C; Liberati AM; Cortelazzo S; Ladetto M;

High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2022 Sep 20;40(27):3120-3131. doi: 10.1200/JCO.21.01393. Epub 2022 Jun 6.

2022
AOU Alessandria
AOU Città della Salute di Torino

Musto P; Boccadoro M; Gay F; Belotti A; Tacchetti P; Fazio F; Zambello R; Luppi M; Liberati AM; Palmieri S; Annibali O; Monaco F; Galieni P; Pisani F; Capra A; Gilestro M; Curci P; Pascarella A; Tosi P; De Sabbata G; Pietrantuono G; Gentile M; Ledda A; Paris L; Morè S; Corradini P; Rota-Scalabrini D; Oliva S; Bertamini L; et alii...

Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience. in Clinical lymphoma, myeloma & leukemia / Clin Lymphoma Myeloma Leuk. 2022 Mar;22(3):198-204. doi: 10.1016/j.clml.2021.09.018. Epub 2021 Sep 2

2022
AOU Città della Salute di Torino

Botto B; Bolis S; Pavone V; Fabbri A; Cantonetti M; Galieni P; Gini G; Pulsoni A; Puccini B; Rigacci L; Moretti M; Liberati AM; Renzi D; Falchi L;

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. in The Lancet. Haematology / Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9.

2022
AOU Città della Salute di Torino

Dimopoulos MA; Richardson PG; Bahlis NJ; Grosicki S; Cavo M; Beksaç M; Legie? W; Liberati AM; Goldschmidt H; Belch A; Magen H; Larocca A; Laubach JP; Petrucci MT; Reece D; White D; Mateos MV; Špi?ka I; Lazaroiu M; Berdeja J; Kaufman JL; Jou YM; Ganetsky A; Popa McKiver M; Lonial S; Weisel K;

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. in European journal of haematology / Eur J Haematol. 2022 Jan;108(1):73-83. doi: 10.1111/ejh.13706. Epub 2021 Sep 22.

2022
AOU Città della Salute di Torino

Larocca A; Yagci M; Robak P; Liberati AM; Galli M; Lindsay J; Oriol A; Beksac M; Salomo M; Pavic M; Dürig J; Jenner M; Corso A; Engelhardt M; Sonneveld P; Rodriguez-Otero P; White D; Anderson LD Jr; Moreau P; Weisel K; Schjesvold F; Richardson PG; Vural F; Kanate AS; Jiang R; Grote L; Peluso T; Dimopoulos M;

Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients. in Clinical cancer research : an official journal of the American Association for Cancer Research / Clin Cancer Res. 2021 Jul 1;27(13):3695-3703. doi: 10.1158/1078-0432.CCR-21-0134. Epub 2021 Apr 29.

2021
AOU Città della Salute di Torino

Hájek R; Spencer A; Nagler A; Gaidano G; Belotti A; Benevolo G; Patriarca F; Mina R; Ruggeri M; Cascavilla N; de Fabritiis P; Mannina D; Liberati AM; Romano A; Capra A; Corradini P; Offidani M; Petrucci MT; Bertamini L; Zaccaria GM; Sonneveld P; Musto P; Boccadoro M; Gay F;

MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. in The Lancet. Haematology / Lancet Haematol. 2021 Feb;8(2):e110-e121. doi: 10.1016/S2352-3026(20)30366-5.

2021
AOU Città della Salute di Torino
AOU Novara

Liberati AM; Novak U; Osborne W; Frezzato M; Fox CP; Davies A; Cascavilla N; Bernardi M; Gastaldi E; Cozens K; Bromberg JEC; Singh V; Fanni A; Re F; Patti C; McKay P; Olivieri J; Linton K; Nassi L; Cellini C; Botto B; Cattaneo C; Khwaja J; Luppi M; Calimeri T; Doorduijn JK; Re A; Cabras MG; Smith J; et alii...

Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial. in Blood cancer journal / Blood Cancer J. 2021 Dec 7;11(12):197. doi: 10.1038/s41408-021-00590-5.

2021
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino

Larocca A; Corradini P; Monaco F; Boccadoro M; Ballanti S; Offidani M; De Paoli L; De Sabbata G; Aquino S; Paris L; Grasso M; Belotti A; Cellini C; Tacchetti P; Zambello R; Musolino C; Cea M; Bonello F; Rota-Scalabrini D; Patriarca F; Capra A; Petrucci MT; Ciccone G; Liberati AM; Pescosta N; Bringhen S; Falcone AP; Mina R;

Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. in Cancers / Cancers (Basel). 2021 Dec 31;14(1):207. doi: 10.3390/cancers14010207.

2021
AOU Alessandria
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara

Piciocchi A; Cuneo A; Foà R; Rigolin GM; Fazi P; Neri A; Guarini A; Raponi S; Nanni M; De Propris MS; Della Starza I; Ibatici A; Murru R; Ruocco V; Del Giudice I; Varettoni M; Molinari A; Gentile M; Chiarenza A; Laurenti L; Gottardi D; Zinzani PL; Gozzetti A; Tani M; Musuraca G; Orsucci L; Re F; Di Renzo N; Liberati AM; et alii...

Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. in Blood cancer journal / Blood Cancer J. 2021 Apr 12;11(4):73. doi: 10.1038/s41408-021-00464-w.

2021
ASL Torino 4
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Hájek R; Sonneveld P; Boccadoro M; Musto P; Guglielmelli T; Di Raimondo F; Corradini P; Aitoro G; Benevolo G; Giuliani N; Patriarca F; Bonello F; de Fabritiis P; Innao V; Zambello R; Cascavilla N; Derudas D; Capra A; Petrucci MT; Gaidano G; Offidani M; Liberati AM; Larocca A; D'Agostino M; Bringhen S;

Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies. in Haematologica / Haematologica. 2021 Apr 1;106(4):1079-1085. doi: 10.3324/haematol.2019.243428.

2021
AOU Città della Salute di Torino

Mina R; Bonello F; Petrucci MT; Liberati AM; Conticello C; Ballanti S; Musto P; Olivieri A; Benevolo G; Capra A; Gilestro M; Galieni P; Cavo M; Siniscalchi A; Palumbo A; Montefusco V; Gaidano G; Omedé P; Boccadoro M; Bringhen S;

High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). in Haematologica / Haematologica. 2020 Nov 1;105(11):2671-2674. doi: 10.3324/haematol.2019.235705.

2020
AOU Alessandria
AOU Città della Salute di Torino

Della Starza I; Del Giudice I; Cuneo A; Albano F; Neri A; Vignetti M; Piciocchi A; Nanni M; Musolino C; Del Poeta G; Battistini R; Gozzetti A; Pietrasanta D; Reda G; Tedeschi A; Liberati AM; Re F; Angelucci E; Zaja F; Coscia M; Ilariucci F; Soddu S; Molica S; Mauro FR; De Propris MS; Raponi S; Guarini AR; Foà R;

Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study. in Blood cancer journal / Blood Cancer J. 2020 May 18;10(5):58. doi: 10.1038/s41408-020-0326-1.

2020
ASL Asti
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino

Larocca A; Romano A; Sonneveld P; Ria R; Musto P; Liberati AM; Offidani M; Giuliani N; Marchetti M; Mosca-Siez ML; de Fabritiis P; Gobbi M; Ballanti S; Cellini C; Grasso M; Monaco F; Ronconi S; Pescosta N; Di Lullo G; Capra A; Belotti A; Petrucci MT; Boccadoro M; Zambello R; Mina R;

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. in The Lancet. Haematology / Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.

2020
AOU Città della Salute di Torino

Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; et alii...

Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi. in Journal of geriatric oncology / J Geriatr Oncol. 2020 Jan;11(1):37-40. doi: 10.1016/j.jgo.2019.06.020. Epub 2019 Jul 8.

2020
AOU Alessandria
AOU Città della Salute di Torino
AOU Novara

Luminari S; Zanni M; Scalone R; Ferrero S; Bari A; Matteucci P; Conconi A; Molinari AL; Liberati AM; Tani M; Gini G; Ferrari A; Nassi L; Merli M; Merli F; Tucci A; Musuraca G; Salvi F; Cavallo F; Mammi C;

Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. in Haematologica / Haematologica. 2020 Jan;105(1):193-200. doi: 10.3324/haematol.2019.219139. Epub 2019 Jun 20.

2020
AOU Città della Salute di Torino
AOU Novara

Corradini P; Cavo M; Offidani M; Liberati AM; Sonneveld P; Hajek R; Nagler A; Ben-Yehuda D; Cascavilla N; Nozzoli C; Ballanti S; Galieni P; Patriarca F; Musto P; Musolino C; Ribolla R; De Paoli L; Di Raimondo F; Spada S; Boccadoro M; Gay F; Montefusco V;

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. in Haematologica / Haematologica. 2020 Apr;105(4):1074-1080. doi: 10.3324/haematol.2019.220657. Epub 2019 Jun 27.

2020
AOU Città della Salute di Torino

Palumbo A; De Paoli L; Romano A; Zambello R; Falcone AP; Giuliani N; Paris L; Fraticelli V; Amico V; Musto P; Bernardini A; Cangiolosi C; Innao V; Oddolo D; Benevolo G; Spada S; Evangelista A; Patriarca F; Ledda A; Liberati AM; Offidani M; Mina R; Larocca A; Montefusco V; Hájek R; Boccadoro M; Bringhen S;

Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis. in Cancer / Cancer. 2019 Mar 1;125(5):750-760. doi: 10.1002/cncr.31854. Epub 2018 Dec 18.

2019
AOU Città della Salute di Torino

Sonneveld P; Cavo M; Palumbo A; Rocci A; Liberati AM; Offidani M; Gamberi B; Troia R; Bernardini A; Conticello C; Larocca A; Grammatico S; Saraci E; Gilestro M; Muccio VE; Spada S; Omedé P; Gambella M; Boccadoro M; Oliva S; Gambella M; Omedé P; Spada S; Muccio VE; Gilestro M; Saraci E; Grammatico S; Larocca A; Conticello C; et alii...

Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (?70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL). in Leukemia & lymphoma / Leuk Lymphoma. 2019 Dec;60(12):2890-2898. doi: 10.1080/10428194.2019.1608529. Epub 2019 Jul 8.

2019
AOU Città della Salute di Torino
AOU Novara

Peli A; Pavone V; Volpetti S; Tani M; Pulsoni A; Arcari A; Patti C; Nassi L; Musuraca G; Freilone R; Centurioni R; Re A; Zanni M; Stelitano C; Liberati AM; Massidda S; Tucci A; Luminari S; Salvi F; Evangelista A; Spina M; Ladetto M; Merli F;

Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study). in The oncologist / Oncologist. 2018 Sep;23(9):1033-1038. doi: 10.1634/theoncologist.2017-0597. Epub 2018 Apr 19.

2018
AOU Alessandria
AOU Città della Salute di Torino

Argnani L; Ricciuti G; Lucania A; Liberati AM; Musuraca G; Gini G; Cavaliere M; Califano C; Volpetti S; Castellino A; Marasca R; Fama A; Arcaini L; Visco C; Rusconi C; Cox MC; Ballerini F; Cantonetti M; Ansuinelli M; Bernocco E; Figuera A; Cencini E; Tani M; Baldini L; Broccoli A; Pellegrini C; Stefoni V; Zinzani PL; Stefoni V; et alii...

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis. in JAMA oncology / JAMA Oncol. 2018 Oct 1;4(10):1389-1397. doi: 10.1001/jamaoncol.2018.2961.

2018
AOU Città della Salute di Torino

Gay F; Jackson G; Rosiñol L; Holstein SA; Moreau P; Spada S; Davies F; Lahuerta JJ; Leleu X; Bringhen S; Evangelista A; Hulin C; Panzani U; Cairns DA; Di Raimondo F; Macro M; Liberati AM; Pawlyn C; Offidani M; Spencer A; Hájek R; Terpos E; Morgan GJ; Bladé J; Sonneveld P; San-Miguel J; McCarthy PL; Ludwig H; Boccadoro M; et alii...

Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma. in Leukemia & lymphoma / Leuk Lymphoma. 2018 May;59(5):1271-1273. doi: 10.1080/10428194.2017.1372575. Epub 2017 Sep 11.

2018
AOU Città della Salute di Torino

Bringhen S; Ballanti S; Pulini S; Liberati AM; Offidani M; Corvatta L;

Early consolidation with high-dose therapy and autologous stem cell transplantation is a feasible and effective treatment option in HIV-associated non-Hodgkin lymphoma at high risk. in Bone marrow transplantation / Bone Marrow Transplant. 2018 Feb;53(2):228-230. doi: 10.1038/bmt.2017.230. Epub 2017 Oct 9.

2018
AOU Città della Salute di Torino

Michieli M; Verga L; Allione B; Spina M; Bocci C; Skert C; Casari S; Cattaneo C; Tozzi P; Liberati AM; Bandera A; Levis A; Rupolo M; Gini G; Re A; Almici C; Leali PF; Tirelli U; Rossi G;

Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study. in Leukemia / Leukemia. 2018 Aug;32(8):1803-1807. doi: 10.1038/s41375-018-0024-1. Epub 2018 Jan 30.

2018
AOU Città della Salute di Torino

Palumbo A; Lombardo A; Bertazzoni P; Rossi G; De Paoli L; Fanin R; Troia R; Patriarca F; Gaidano G; Belotti A; Spada S; Liberati AM; Cafro AM; Mina R; Bringhen S; Sonneveld P; Boccadoro M; Bringhen S; Mina R; Cafro AM; Liberati AM; Spada S; Belotti A; Gaidano G; Patriarca F; Troia R; Fanin R; De Paoli L; Rossi G; et alii...

Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. in Leukemia / Leukemia. 2018 Apr;32(4):979-985. doi: 10.1038/leu.2017.327. Epub 2017 Nov 16.

2018
AOU Città della Salute di Torino
AOU Novara

Boccadoro M; Sonneveld P; Corradini P; Palumbo A; Gaidano G; Ballanti S; Petrucci MT; Offidani M; Musto P; De Angelis C; Esma F; Muccio VE; Liberati AM; Galieni P; Grammatico S; Montefusco V; De Paoli L; D'Agostino M; Bringhen S;

Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. in Haematologica / Haematologica. 2017 Sep;102(9):e352-e355. doi: 10.3324/haematol.2016.156901. Epub 2017 Jun 8.

2017
AO Ordine Mauriziano
AOU Città della Salute di Torino

Piciocchi A; Boncompagni R; Orlando S; Cuneo A; Galieni P; Marasca R; Vannata B; Pozzato G; Efremov DG; Molica S; Coscia M; Massaia M; D'Arena G; Del Poeta G; Mannina D; Mauro FR; Ciolli S; Autore F; Innocenti I; Laurenti L; Vincelli D; Liberati AM; Russo F; Foá R; Laurenti L; Innocenti I; Autore F; Ciolli S; Mauro FR; et alii...

Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma. in Oncotarget / Oncotarget. 2017 May 23;8(53):91703-91710. doi: 10.18632/oncotarget.18114. eCollection 2017 Oct 31.